Any organisation that manufactures, imports, exports, or distributes regulated health products in South Africa must hold a valid SAHPRA Establishment Licence.
GH Strategies provides structured, end to end licensing support across pharmaceutical, medical device, and cannabis sectors, ensuring your organisation is compliant, audit ready, and positioned for sustainable market participation.
What GH Strategies Delivers
Regulatory Strategy Aligned to Licence Scope
We define the correct licensing pathway based on your operational model, product category, and SAHPRA requirements, ensuring alignment between your declared activities and licence type.
Establishment Licence Application Preparation
We prepare complete, structured licence applications across pharmaceutical, medical device, and cannabis categories, ensuring technical accuracy and submission readiness.
Quality System Alignment for Approval
We align your Quality Management System with SAHPRA expectations and relevant standards such as ISO 13485, GMP, and GDP to support licensing success.
Facility and Operational Compliance Readiness
We assess your facility, distribution model, and operational controls to ensure they meet regulatory expectations before submission.
SAHPRA Liaison and Query Management
We manage communication with SAHPRA throughout the review process, ensuring queries are addressed clearly, completely, and efficiently.
Post Licence Compliance and Maintenance
We support ongoing compliance through renewals, amendments, inspections, and regulatory updates to ensure your licence remains valid and defensible.
Planning to manufacture, import, or distribute health products in South Africa?
Speak to an Expert.
Establishment Licence Pathways
Each SAHPRA licence process has specific regulatory requirements, documentation expectations, and operational implications.
Pharmaceutical Establishment Licence
For companies involved in the manufacture, importation, export, or wholesale of human or veterinary medicines.
This pathway requires alignment with GMP and GDP standards, detailed operational controls, and structured regulatory documentation.
Medical Device Establishment Licence
For manufacturers, distributors, and importers of medical devices and in vitro diagnostics.
This pathway is closely linked to ISO 13485 quality systems, device classification, and distribution controls.
Cannabis Establishment Licence
For organisations operating within the cannabis and controlled substances regulatory framework.
This pathway requires strict compliance with controlled substance regulations, security measures, and specialised operational oversight.
Four Pillars of a SAHPRA-Ready Establishment
Your declared activities must accurately reflect your operational scope. Misalignment between activities and licence type is one of the most common causes of delays.
Your organisation must demonstrate control over procurement, storage, distribution, documentation, and quality oversight aligned with regulatory expectations.
Storage conditions, environmental controls, traceability systems, and distribution pathways must align with the product category and associated risks.
SAHPRA requires clearly defined roles, including responsible persons and quality oversight structures that demonstrate governance and accountability.
Strategic Value of an Establishment Licence
A SAHPRA Establishment Licence is not only a regulatory requirement. It is a strategic enabler of market access and operational credibility.
It allows your organisation to legally operate within the South African market, strengthens your position with global partners, and enables smoother product registration and distribution.
A well structured licence application also reduces regulatory risk, supports audit readiness, and positions your organisation for expansion into broader African markets.
Frequently Asked Questions (FAQs)
Any organisation involved in the manufacture, importation, export, or distribution of regulated health products in South Africa must obtain a SAHPRA Establishment Licence. This includes pharmaceutical companies, medical device distributors, cannabis operators, and third party logistics providers handling regulated products within the supply chain.
Yes. Foreign manufacturers cannot operate independently within South Africa’s regulatory framework and must either establish a locally licensed entity or appoint a South African regulatory representative. This ensures compliance with SAHPRA requirements, regulatory communication, and ongoing post market obligations within the country.
SAHPRA evaluates the risk classification of the products, the nature of the activities performed, and the level of quality system maturity when determining whether a facility inspection is required. Higher risk operations, including manufacturing and complex distribution environments, are more likely to undergo inspection prior to licence approval.
Yes. Warehousing and third party logistics providers handling regulated pharmaceutical or medical device products must hold their own SAHPRA Establishment Licence if they perform storage, distribution, or handling activities. Their operations must comply with GDP requirements and demonstrate appropriate environmental and traceability controls.
Yes. GH Strategies supports both new entrants and established organisations by providing structured regulatory guidance, licensing strategy, and quality system alignment. This ensures companies entering regulated sectors meet SAHPRA requirements from the outset and avoid costly compliance delays or application rejections.
Common causes of delays include incomplete documentation, incorrect activity classification, weak quality management systems, and misalignment between operational practices and regulatory expectations. Ensuring technical accuracy and regulatory alignment from the start significantly improves approval timelines and reduces the risk of rejection.
Let’s Build Something That Lasts
Strengthen your approval prospects with a device-specific licensing readiness review.